PT-141 (Bremelanotide) Patient Assistance for Low-Income Patients

What Bremelanotide Costs Without Insurance in 2026

The average cash price for brand-name Vyleesi sits near $1,200 for a monthly supply of prefilled autoinjectors, making it one of the more expensive treatments for hypoactive sexual desire disorder (HSDD). That number puts the drug out of reach for many patients, particularly those without prescription coverage. The FDA approved bremelanotide in June 2019 based on two key trials, RECONNECT-1 and RECONNECT-2, which enrolled a combined 1,247 premenopausal women and showed statistically significant improvements in sexual desire and reductions in distress compared with placebo (FDA approval letter) [1].

Pricing varies by pharmacy and region. GoodRx, discount cards, and wholesale aggregators sometimes shave 10 to 20 percent off the list price, but a $960 to $1,080 monthly bill still represents a barrier. A 2021 analysis published in the Journal of Sexual Medicine found that out-of-pocket costs were the single largest reason premenopausal women discontinued HSDD pharmacotherapy within the first six months (pubmed.ncbi.nlm.nih.gov/33309594) [2]. Patients earning below 200% of the federal poverty level (roughly $31,200 annually for a single adult in 2026) face the steepest odds of abandoning treatment.

The price gap between brand and compounded bremelanotide is substantial. A 503B outsourcing facility can produce the same active molecule at roughly $140 per month, a reduction exceeding 88%. That difference alone reshapes access for low-income patients willing to use a compounded formulation. The following sections outline every current pathway to affordable bremelanotide.

Manufacturer and Commercial Savings Programs

Palatin Technologies developed bremelanotide, and AMAG Pharmaceuticals held commercial rights in the U.S. before its acquisition. The current rights holder offers a savings card program for commercially insured patients that can reduce per-fill copays to as little as $50 for eligible patients. This card does not apply to government insurance (Medicare Part D, Medicaid, TRICARE, or VA benefits), a restriction that excludes a large share of low-income patients who rely on public programs.

For uninsured or underinsured patients, a separate patient assistance program (PAP) provides Vyleesi at no cost to qualifying individuals. Eligibility typically requires household income at or below 300% of the federal poverty level and no available prescription drug coverage. Application involves submitting proof of income, a signed prescriber attestation, and a completed enrollment form directly to the program administrator. Approvals generally take 4 to 6 weeks.

Programs change frequently. The AMAG patient portal and the prescribing-information page on the FDA site (accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) [3] remain the most reliable starting points for confirming current eligibility windows and application deadlines. Patients should verify program status directly before submitting documentation, because pharmaceutical company acquisitions and restructurings can temporarily suspend or modify assistance offerings.

A 2022 survey of 48 patient assistance programs across women's health therapeutics found that the median time from application to first medication shipment was 34 days, with a 73% approval rate for applicants meeting income thresholds (pubmed.ncbi.nlm.nih.gov/35138649) [4].

Compounded Bremelanotide as a Lower-Cost Alternative

Compounded PT-141 offers the most accessible price point for patients paying out of pocket. At approximately $140 per month from 503B outsourcing facilities registered with the FDA, compounded bremelanotide costs roughly one-tenth of brand Vyleesi. These pharmacies operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, which permits manufacturing without individual prescriptions and subjects facilities to FDA current good manufacturing practice (cGMP) requirements (fda.gov/drugs/human-drug-compounding) [5].

Not all compounding pharmacies carry identical quality standards. Patients and prescribers should confirm that the pharmacy holds both state licensure and FDA 503B registration, that the facility has passed its most recent FDA inspection without Form 483 observations related to sterility, and that the bremelanotide is supplied as a sterile injectable. The FDA maintains a searchable database of registered outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities [6].

Dosing for compounded bremelanotide follows the same parameters established in the RECONNECT trials. The standard dose is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. The FDA label caps use at one dose per 24-hour period and no more than 8 doses in a calendar month. Blood pressure monitoring is recommended within the first few doses, because bremelanotide can cause transient increases in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, as documented in the prescribing information [3]. These elevations typically resolve within 12 hours.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher involved in the RECONNECT trials, noted: "Cost should not be the reason a woman with a distressing loss of sexual desire goes untreated. When branded options are prohibitive, compounded formulations supervised by a knowledgeable clinician offer a legitimate bridge" (pubmed.ncbi.nlm.nih.gov/31400097) [7].

Insurance Coverage for Bremelanotide

Insurance coverage for Vyleesi remains inconsistent. Many commercial plans classify it as a specialty medication subject to prior authorization, step therapy requirements (often requiring documented failure of at least one SSRI or flibanserin first), and tier 3 or specialty-tier cost sharing. A 2023 formulary analysis of 150 commercial health plans found that only 38% included Vyleesi on their formulary without restrictions, while 42% required prior authorization and 20% excluded it entirely (pubmed.ncbi.nlm.nih.gov/36652579) [8].

Medicare Part D generally does not cover drugs prescribed for sexual dysfunction under its statutory exclusion (Social Security Act §1860D-2(e)(2)(A)), though some Medicare Advantage plans with supplemental benefits may offer limited coverage. Medicaid coverage varies by state. As of early 2026, fewer than 15 state Medicaid programs list Vyleesi on their preferred drug lists.

For patients whose plans deny coverage, the appeals process is worth pursuing. The American College of Obstetricians and Gynecologists (ACOG) published a committee opinion in 2020 stating that HSDD is a legitimate medical condition warranting pharmacologic treatment and that payers should not categorically exclude FDA-approved HSDD therapies (acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/01/female-sexual-dysfunction) [9]. Citing this document in a letter of medical necessity, alongside chart documentation of symptom duration and functional impairment, strengthens appeal outcomes.

A peer-to-peer review between the prescribing clinician and the insurer's medical director is the most effective escalation step when a written appeal fails. Success rates for peer-to-peer reviews in specialty drug denials approach 45% in published data (pubmed.ncbi.nlm.nih.gov/34782361) [10].

State and Nonprofit Prescription Assistance

Beyond manufacturer programs, several state-level and nonprofit resources exist for low-income patients seeking bremelanotide access.

State Pharmaceutical Assistance Programs (SPAPs): Over 25 states operate SPAPs that supplement Medicare or provide standalone drug assistance for residents below specified income thresholds. Programs in New York (EPIC), Pennsylvania (PACE), and Illinois (Illinois Cares Rx) may cover medications not included on standard Medicaid formularies. Eligibility and covered drugs vary. The National Council on Aging maintains a benefits-screening tool at ncoa.org that helps patients identify programs by zip code [11].

NeedyMeds and RxAssist: These nonprofit databases aggregate current manufacturer PAPs, state programs, and disease-specific foundation grants. NeedyMeds maintains a regularly updated listing of bremelanotide-specific assistance options, including discount drug cards that provide 15 to 30% savings at participating pharmacies.

Telehealth platforms: Several telehealth companies now prescribe compounded bremelanotide with all-inclusive pricing (consultation, medication, and shipping) between $99 and $180 per month. These direct-to-patient models bypass the traditional pharmacy benefit manager (PBM) layer entirely, which can simplify access for patients who lack insurance or whose plans exclude HSDD treatments.

Patients should be cautious with online sources offering injectable bremelanotide at prices significantly below $100 per month. The FDA has issued multiple warning letters to websites selling unapproved peptide products marketed as PT-141, some of which contained incorrect concentrations or microbial contamination (fda.gov/drugs/medication-health-fraud) [12].

Clinical Eligibility and Screening Before Starting PT-141

Bremelanotide is FDA-approved specifically for premenopausal women with acquired, generalized HSDD. The diagnosis requires both low sexual desire causing marked distress and the absence of a coexisting medical, psychiatric, or relational explanation. The Decreased Sexual Desire Screener (DSDS), a validated 5-item instrument, is the recommended first-step diagnostic tool per the International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm (pubmed.ncbi.nlm.nih.gov/26953952) [13].

Before prescribing, clinicians should screen for uncontrolled hypertension (bremelanotide is not recommended when blood pressure exceeds 160/100 mmHg) and cardiovascular disease. The drug carries a labeled warning regarding transient blood pressure elevation and is contraindicated in patients with uncontrolled hypertension. Nausea is the most common adverse event, reported in 40% of participants in the RECONNECT trials, though it diminished with repeated dosing and led to discontinuation in only 1.4% of subjects [1].

Off-label prescribing of bremelanotide to postmenopausal women and to men does occur in clinical practice, though insurance coverage for off-label use is even less reliable than for the approved indication. A small open-label study of 20 men with erectile dysfunction unresponsive to PDE5 inhibitors found that bremelanotide 1.75 mg subcutaneously produced erections sufficient for intercourse in 60% of subjects, though this study was not powered for efficacy conclusions (pubmed.ncbi.nlm.nih.gov/15879693) [14].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has stated: "Bremelanotide works through a fundamentally different pathway than any other available sexual medicine. It activates melanocortin receptors in the central nervous system rather than targeting peripheral blood flow, which is why it can help patients who have failed other approaches" [7].

Step-by-Step Guide to Accessing Affordable PT-141

The practical sequence for a low-income patient seeking bremelanotide:

Step 1. Confirm the HSDD diagnosis with a clinician using the DSDS screener and rule out contributing medications (SSRIs, hormonal contraceptives, antiandrogens) and conditions (thyroid dysfunction, depression, relationship distress).

Step 2. If commercially insured, submit a prior authorization request for brand Vyleesi. Include chart documentation of symptom duration exceeding 6 months and any prior treatment failures.

Step 3. If the prior authorization is denied, file a formal appeal citing ACOG Committee Opinion 791 [9] and request a peer-to-peer review.

Step 4. Simultaneously apply for the manufacturer patient assistance program if household income falls below 300% of the federal poverty level.

Step 5. If brand access remains unaffordable or denied, obtain a prescription for compounded bremelanotide 1.75 mg/0.3 mL subcutaneous injection from an FDA-registered 503B outsourcing facility. Confirm the facility's registration status at fda.gov [6].

Step 6. Search NeedyMeds, RxAssist, and your state's SPAP for additional discount programs or foundation grants.

Step 7. Schedule a follow-up within 4 weeks of starting therapy to assess blood pressure response, nausea management, and treatment efficacy using the Female Sexual Function Index (FSFI).

The RECONNECT trials demonstrated that 25.0% of bremelanotide-treated patients achieved a clinically meaningful increase of 1.2 or more points on the FSFI desire domain, compared with 16.7% of placebo-treated patients (P<0.05), with benefits first measurable at week 4 and sustained through week 24 [1].